SCHEMBL23705752

SCHEMBL23705752

N#Cc1ccc(COCC(N)C(=O)Nc2nc(-c3ccccc3)cs2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRE11 P49959 9/20 0.52
KDM4E B2RXH2 2/20 0.51
MAPT P10636 2/20 0.51
MEN1 O00255 1/20 0.51
GAA P10253 1/20 0.51
HTT P42858 1/20 0.51
KMT2A Q03164 1/20 0.51
HDAC6 Q9UBN7 3/20 0.50
ELOVL1 Q9BW60 1/20 0.47
HDAC3 O15379 2/20 0.46
HDAC4 P56524 2/20 0.46
HDAC1 Q13547 2/20 0.46
HDAC7 Q8WUI4 2/20 0.46
HDAC2 Q92769 2/20 0.46
HDAC10 Q969S8 2/20 0.46
HDAC11 Q96DB2 2/20 0.46
HDAC8 Q9BY41 2/20 0.46
HDAC9 Q9UKV0 2/20 0.46
HDAC5 Q9UQL6 2/20 0.46
APP P05067 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23705751 1.00 MRE11 (0.52) MRE11KDM4EMAPTMEN1GAA
SCHEMBL23729267 0.89 MRE11 (0.52) MRE11KDM4EMAPTMEN1GAA
SCHEMBL23705549 0.87 HDAC6 (0.52) MRE11KDM4EMAPTMEN1KMT2A
SCHEMBL23705551 0.87 HDAC6 (0.52) MRE11KDM4EMAPTMEN1KMT2A
SCHEMBL26614504 0.83 CTSS (0.58) MRE11KDM4EMAPTMEN1GAA
SCHEMBL26614511 0.83 CTSS (0.58) MRE11KDM4EMAPTMEN1GAA
SCHEMBL23705742 0.82 HDAC6 (0.47) MRE11MAPTMEN1KMT2AHDAC6
SCHEMBL23705746 0.82 HDAC6 (0.47) MRE11MAPTMEN1KMT2AHDAC6
SCHEMBL23729766 0.81 SMARCA2 (0.46) MRE11KDM4EMAPTMEN1GAA
SCHEMBL30058675 0.80 HDAC6 (0.49) MRE11MAPTMEN1KMT2AHDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348452-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-11-02 US disclosed
US-20230348452-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-11-02 US disclosed
US-20230348452-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-11-02 US disclosed
EP-4097096-A2 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2022-12-07 EP disclosed
WO-2021155321-A2 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed
WO-2021155321-A2 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348452-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, BRCA1 MRE11 1424/4885KDM4E 2184/4885MAPT 1920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.